| A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment J Shen, S Najafi, S Stäble, J Fabian, E Koeneke, FR Kolbinger, JK Wrobel, ... Cell Death & Differentiation 25 (12), 2053-2070, 2018 | 32 | 2018 |
| Rapid in vivo validation of HDAC inhibitor-based treatments in neuroblastoma zebrafish xenografts JK Wrobel, S Najafi, S Ayhan, C Gatzweiler, D Krunic, J Ridinger, T Milde, ... Pharmaceuticals 13 (11), 345, 2020 | 23 | 2020 |
| Functional therapeutic target validation using pediatric zebrafish xenograft models C Gatzweiler, J Ridinger, S Herter, XF Gerloff, D ElHarouni, Y Berker, ... Cancers 14 (3), 849, 2022 | 22 | 2022 |
| The first-in-class erk inhibitor ulixertinib shows promising activity in mapk-driven pediatric low-grade glioma models R Sigaud, L Rösch, C Gatzweiler, J Benzel, L von Soosten, H Peterziel, ... Neuro-Oncology, 2022 | 19* | 2022 |
| Broad-spectrum HDAC inhibitors promote autophagy through FOXO transcription factors in neuroblastoma K Körholz, J Ridinger, D Krunic, S Najafi, XF Gerloff, K Frese, B Meder, ... Cells 10 (5), 1001, 2021 | 19 | 2021 |
| Combining APR-246 and HDAC-inhibitors: a novel targeted treatment option for neuroblastoma M Müller, L Rösch, S Najafi, C Gatzweiler, J Ridinger, XF Gerloff, ... Cancers 13 (17), 4476, 2021 | 11 | 2021 |
| ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein L Rösch, S Herter, S Najafi, J Ridinger, H Peterziel, J Cinatl, DTW Jones, ... Molecular Oncology 17 (1), 37-58, 2023 | 4 | 2023 |
| LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK … R Sigaud, L Roesch, C Gatzweiler, J Benzel, L von Soosten, H Peterziel, ... Neuro-Oncology 24 (Suppl 1), i93, 2022 | 4 | 2022 |
| Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours T Seiboldt, C Zeiser, D Nguyen, S Celikyürekli, S Herter, S Najafi, ... British journal of cancer 131 (4), 763-777, 2024 | 1 | 2024 |
| Evaluation of Antitumor and On-Target Activity of HDAC Inhibitors with the Zebrafish Embryo Xenograft Model C Gatzweiler, J Ridinger, S Ayhan, S Najafi, H Peterziel, O Witt, I Oehme HDAC/HAT Function Assessment and Inhibitor Development: Methods and …, 2022 | 1 | 2022 |
| Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins M Halilovic, M Abdelsalam, J Zabkiewicz, M Lazenby, C Alvares, ... Leukemia, 1-12, 2024 | | 2024 |
| The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models. R Sigaud, D Knoerzer, I Büdenbender, A Korshunov, H Peterziel, F Selt, ... Neuro-Oncology 25 (DKFZ-2022-01552), 566-579, 2023 | | 2023 |
| Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11 phosphorylation. V Mlakar, I Oehme, L Lesne, S Najafi, M Ansari, F Gumy-Pause | | 2022 |
| Zebrafish xenografts of pediatric nervous system tumors for rapid in vivo validation of small molecule inhibitor-based combination treatments S Najafi | | 2020 |
| Targeted neuroblastoma therapy and the development of autophagy-mediated drug resistance in the zebrafish xenograft model S Najafi, JK Wrobel, H Peterziel, B Meder, M Distel, O Witt, I Oehme Klinische Pädiatrie 229 (03), A38, 2017 | | 2017 |
Benjamin MederW3 Professor for Precision Digital Health, University of Heidelberg在 benegfx.de 的电子邮件经过验证
